Oncogenic PIK 3 CA-driven mammary tumors frequently recur via PI 3 K pathway – dependent and PI 3 K pathway – independent mechanisms

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• POSTER PRESENTATION Open Access

  2013cited by this paper
• Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

  2010cited by this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010cited by this paper
• Targeting the phosphoinositide 3-kinase pathway in cancer

  2009cited by this paper
• Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

  2009cited by this paper
• High‐resolution genomic and expression analyses of copy number alterations in breast tumors

  2008cited by this paper
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

  2008cited by this paper
• An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  2008cited by this paper
• PI3K pathway alterations in cancer: variations on a theme

  2008cited by this paper
• An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

  2007cited by this paper
• Cancer-specific mutations in phosphatidylinositol 3-kinase.

  2007cited by this paper
• Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

  2006cited by this paper
• A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.

  2006cited by this paper
• The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells

  2005cited by this paper
• Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

  2005cited by this paper
• Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

  2005cited by this paper
• The transcriptional repressor Snail promotes mammary tumor recurrence.

  2005cited by this paper
• Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

  2005cited by this paper
• Determination of subcutaneous tumor size in athymic (nude) mice

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays.

  2004cited by this paper
• A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells

  2004cited by this paper
• A novel doxycycline‐inducible system for the transgenic analysis of mammary gland biology

  2002cited by this paper
• Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.

  2002cited by this paper
• Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

  2000cited by this paper
• Variations on a theme.

  1990cited by this paper

• Decoding MYC Targeted Inhibition in Cancer: Integrating Medicinal Insights With Computational Design Approaches

  2026cites this paper
• Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer

  2026cites this paper
• Targeting PI3Kβ-dependent cancer with a novel small molecule inhibitor, GT220

  2026cites this paper
• Predicting and Confirming Bioequivalence of Alpelisib Oral Granules and Tablets for Patients With PIK3CA-Related Disorders

  2025cites this paper
• Особенности лучевой диагностики у детей с дисплазией магистральных вен нижних конечностей

  2025cites this paper
• miR-21-5p Targets PIK3R1 to Regulate the NF-κB Signaling Pathway, Inhibiting the Invasion and Progression of Prolactinoma

  2025cites this paper
• Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology

  2024cites this paper
• Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis

  2024cites this paper
• PI3Kβ controls immune evasion in PTEN-deficient breast tumours

  2023cites this paper
• Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice

  2023cites this paper
• Lipocalin 2 potentially contributes to tumorigenesis from colitis via IL-6/STAT3/NF-κB signaling pathway

  2022cites this paper
• Exploring the Neoantigen burden in Breast Carcinoma Patients

  2022cites this paper
• Upregulation of Receptor Tyrosine Kinase Activity and Stemness as Resistance Mechanisms to Akt Inhibitors in Breast Cancer

  2022cites this paper
• Accelerating Breast Cancer Biomarker Discovery by Mass Spectrometry Proteomics and Current Bioinformatics Tools

  2022cites this paper
• Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma

  2022cites this paper
• AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B.

  2021cites this paper
• Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

  2021cites this paper
• Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer

  2021cites this paper
• DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway

  2021cites this paper
• WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.

  2021cites this paper
• Edinburgh Research Explorer NODAL/TGF signalling mediates the self-sustained stemness induced by PIK3CAH1047R homozygosity in pluripotent stem cells

  2021cites this paper
• NODAL/TGFβ signalling mediates the self-sustained stemness induced by <italic>PIK3CA^H1047R</italic> homozygosity in pluripotent stem cells

  2021cites this paper
• New derivatives of sulfonylhydrazone as potential antitumor agents: Design, synthesis and cheminformatics evaluation

  2021cites this paper
• Copanlisib in non-Hodgkin's lymphoma and solid tumors: An efficacy and safety analysis

  2021cites this paper
• Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients

  2020cites this paper
• Synergistic Carcinogenesis of HPV18 and MNNG in Het-1A Cells through p62-KEAP1-NRF2 and PI3K/AKT/mTOR Pathway

  2020cites this paper
• Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort

  2019cites this paper
• NODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CAH1047R homozygosity in pluripotent stem cells

  2019cites this paper
• Designing Rational Combination Strategies for Overcoming Drug Resistance in Breast Cancer

  2019cites this paper
• Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation

  2019cites this paper
• Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors.

  2019cites this paper
• Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer

  2018cites this paper
• Development and characterisation of a panel of phosphatidylinositide 3-kinase – mammalian target of rapamycin inhibitor resistant lung cancer cell lines

  2018cites this paper
• Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner

  2018cites this paper
• Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics

  2018cites this paper
• Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients

  2018cites this paper
• Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer

  2018cites this paper
• Synthetic Lethal Interactions With Oncogenic KRAS

  2018cites this paper
• Progressive polarity loss and luminal collapse disrupt tissue organization in carcinoma

  2017cites this paper
• Frequent PIK3CA activating mutations in nipple adenomas

  2017cites this paper
• MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.

  2017cites this paper
• Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.

  2017cites this paper
• Effects of PI3K and FSH on steroidogenesis, viability and embryo development of the cumulus–oocyte complex after in vitro culture

  2017cites this paper
• ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis

  2017cites this paper
• Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development

  2017cites this paper
• Inhibitors of STAT3, β‐catenin, and IGF‐1R sensitize mouse PIK3CA‐mutant breast cancer to PI3K inhibitors

  2017influential citation
• Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis

  2017cites this paper
• PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors

  2017cites this paper
• Synergistic interactions with PI3K inhibition that induce apoptosis

  2017cites this paper
• In vivo models in breast cancer research: progress, challenges and future directions

  2017cites this paper
• Oncogenic Roles of the PI3K/AKT/mTOR Axis.

  2017cites this paper
• Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.

  2016cites this paper
• Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer

  2016cites this paper
• PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer.

  2016influential citation
• Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.

  2016cites this paper
• Cooperative genomic alteration network reveals molecular classification across 12 major cancer types

  2016cites this paper
• Cell Fate Decisions During Breast Cancer Development

  2016cites this paper
• Genetically engineered mouse models in oncology research and cancer medicine

  2016cites this paper
• ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP.

  2016cites this paper
• Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition

  2016cites this paper
• Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX1

  2016cites this paper
• Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer

  2016cites this paper
• Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion

  2016cites this paper
• Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas

  2016cites this paper
• The PI3K/AKT Pathway as a Target for Cancer Treatment.

  2016cites this paper
• Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

  2016cites this paper
• Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer

  2016cites this paper
• Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation.

  2016cites this paper
• Analysis of Ras effector pathways in pancreatic cancer progression and maintenance

  2016cites this paper
• Mechanisms of Resistance to MAPK Pathway Inhibition in RAS-Mutant Cancers

  2016cites this paper
• Drugging PI3K in cancer: refining targets and therapeutic strategies

  2015cites this paper
• Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.

  2015influential citation
• MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism

  2015cites this paper
• Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy

  2015cites this paper
• The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis.

  2015cites this paper
• Whole‐exome DNA sequence analysis of Brca2‐ and Trp53‐deficient mouse mammary gland tumours

  2015cites this paper
• Functional Compensation Between Myc and PI3K Signaling Supports Self‐Renewal of Embryonic Stem Cells

  2015cites this paper
• MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

  2015cites this paper
• Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling

  2015cites this paper
• Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer

  2015cites this paper
• Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma

  2015cites this paper
• PIK3CAH1047R and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling

  2015influential citation
• Empirical inference of circuitry and plasticity in a kinase signaling network

  2015cites this paper
• Inmunofenotipos de cáncer de mama en pacientes jovenes (40 años o menores): estudio de la expresión inmunohistoquímica de la vía IGF1R, PTEN/Akt/mTOR

  2015cites this paper
• Relationship between PI3K Mutation and Sodium-Iodide Symporter in Anaplastic Thyroid Carcinoma

  2015cites this paper
• Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity

  2015cites this paper
• The phosphoinositide 3-kinase pathway and therapy resistance in cancer

  2015cites this paper
• PI3K regulatory subunit p85alpha plays a tumor suppressive role in the transformation of mammary epithelial cells

  2015influential citation
• Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.

  2015cites this paper
• Effects of PIK3CA mutations on mammary cell fate and cancer

  2015influential citation
• Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*

  2015cites this paper
• Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors

  2014cites this paper
• Investigating the cellular mechanisms that determine RNMT dependency in breast cancer cells

  2014cites this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cites this paper
• Tetracycline-regulated mouse models of cancer.

  2014influential citation
• PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

  2014cites this paper
• Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

  2014cites this paper
• A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

  2014cites this paper
• Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling

  2014cites this paper
• 1 PI 3 K and Cancer : Lessons , Challenges and Opportunities

  2014cites this paper